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Fatal Case of  
Enterovirus 71  
Infection and  
Rituximab Therapy, 
France, 2012
To the Editor: Enterovirus 71 
(EV-71) causes primarily asymptom-
atic or benign infections in children <5 
years of age. However, it may cause 
severe and sometimes fatal neurolog-
ic complications, such as brainstem 
encephalitis and polio-like paralysis 
(1). Over the last 15 years, large out-
breaks of EV-71 infection have been 
described in the Asia–Pacific region, 
associated with the regular emergence 
of new genetic lineages (2). Since the 
1978 outbreak in Hungary, rare spo-
radic cases have been reported in Eu-
rope (1). In France, during 2000–2009, 
a total of 81 hospitalized patients with 
EV–17 infection were reported by the 
sentinel surveillance system, includ-
ing 2 child deaths, 1 due to proven 
rhombencephalitis (3,4). 
We report here a fatal case of EV-
71 rhombencephalitis in an immuno-
compromised adult who was receiving 
rituximab therapy. Rituximab is a chi-
meric anti-CD20 monoclonal antibody 
that is widely used for treating B-cell 
lymphoma and an increasing number of 
autoimmune diseases. Since rituximab 
became commercially available, sev-
eral infectious side-effects for the drug 
have been reported, including hepatitis 
B reactivation, progressive multifocal 
leukoencephalopathy, and enteroviral 
meningoencephalitis (5). The first 2 
cases of rituximab-associated enterovi-
ral meningoencephalitis were reported 
in 2003 (6), and 5 additional cases have 
been reported to date (7,8).
In May 2012, a 66-year-old wom-
an was hospitalized in the neurology 
unit of Bordeaux University Hospital 
with a 10-day history of fever, asthe-
nia, and psychomotor retardation. She 
had no history of travel and had not 
been in close contact with sick per-
sons. She had received a diagnosis of 
grade I follicular lymphoma 3 years 
earlier, and it had been treated with 6 
cycles of R-CHOP (rituximab, cyclo-
phosphamide, hydroxydaunorubicin, 
oncovin, prednisolone). Since July 
2010, the lymphoma had been in re-
mission, and she had been receiving 
maintenance therapy with rituximab 
since that time. The most recent ritux-
imab infusion had been administered 
in March 2012. Her condition was 
treated initially with broad-spectrum 
antibiotics and acyclovir. Still, apha-
sia, facial paralysis, spastic move-
ments, and consciousness disorders 
rapidly developed. On day 6, she was 
transferred to the intensive care unit 
for ventilatory support.
On patient’s admission, blood 
samples showed lymphopenia (0.64 × 
103 cells/mm3) and low immunoglobu-
lin levels, i.e., IgG 4.5 g/L (reference 
range 6.75–12.8 g/L) and IgM 0.33 
g/L (reference range 0.56–1.9 g/L). 
Three cerebrospinal fluid (CSF) sam-
ples were collected on days 1, 4, and 
6. CSF leukocyte count rose from 5 to 
89 cells/mm3, with lymphocytes from 
24% to 95%, and protein levels rose 
from 0.68 to 1.03 g/L (reference range 
0.15–0.45 g/L). CSF glucose level var-
ied from 3.5 to 4.5 mmol/L (reference 
range 2.7–3.9 mmol/L). Enterovirus 
RNA was detected in the patient’s 
first 3 CSF samples and in CSF, stool 
specimens, and blood until 4 weeks 
after admission (online Technical Ap-
pendix Table 1,  wwwnc.cdc.gov/EID/
article/19/8/13-0202-Techapp1.pdf). 
PCR assays of the first 3 CSF samples 
were negative for JC polyomavirus, 
herpes simplex virus, varicella-zoster 
virus, cytomegalovirus, Epstein-Barr 
virus, human herpesvirus 6, adenovi-
rus, and Toxoplasma gondii. Serologic 
tests for parvovirus B19, mumps virus, 
and measles virus were IgM negative. 
Samples were also negative for anti-
bodies against Hu, Ri, Yo, and voltage-
gated potassium channel antigens. All 
bacterial cultures were negative. No 
evidence for central nervous system 
infiltration by lymphoma cells was 
found, on the basis of CSF cytology.
Results of brain magnetic reso-
nance imaging (MRI) scans performed 
on days 2 and 6 were normal, despite 
the patient’s consciousness disorders 
(Figure, panel A). However, on day 
13, MRI scans showed bilateral and 
symmetric T2 and FLAIR hypersig-
nals in the medulla, the pons, and 
the mesencephalon, compatible with 
rhomboencephalitis (Figure, panel 
B). On day 24, the MRI scan showed 
a supratentorial extension involving 
white matter, the insular cortex, and 
basal ganglia (Figure, panel C). The 
patient’s neurologic condition dete-
riorated progressively, and she died 
of enteroviral rhomboencephalitis 32 
days after admission. 
The EV associated with the rhom-
boencephalitis was identified as an 
EV-71 genogroup C2 isolate by 1D 
gene complete sequencing and phy-
logenetic analysis (online Technical 
Appendix Figure; online Technical 
Appendix Table 2). The 1D gene se-
quences determined from cerebrospi-
nal fluid and fecal specimens from the 
patient showed 95%–97% nucleotide 
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homology and clustered with 1D gene 
sequences from strains detected during 
2006–2012 in France, the Netherlands, 
Germany, Spain, Canada, United 
Kingdom, and Singapore.
Only 7 cases of rituximab-as-
sociated EV encephalitis have been 
reported in the literature. Of the case-
patients, 3 died from enteroviral me-
ningoencephalitis, 1 showed partial 
neurologic improvement but died later 
from another infection (not specified), 
2 suffered permanent sequelae, and 1 
recovered completely (6–8).
The first case of fatal rituximab-as-
sociated EV-71 encephalitis was report-
ed in Australia in 2011 (8). The Aus-
tralian patient and the French patient 
reported here were adults, although 
most EV-71 encephalitis cases have 
been described in children (1). Neither 
adult patient exhibited neurogenic pul-
monary edema. Both cases were associ-
ated with genogroup C2 EV-71 strains 
that were closely related to those that 
have been detected in recent years in 
Europe and worldwide (3).
Because invasive EV infections 
have been described in adults with 
hereditary or congenital defects in 
B-lymphocyte function, humoral im-
munity is likely to play a key role in 
EV infection control (9). Passive pro-
tection against lethal EV-71 infection 
in newborn mice by neutralizing anti-
bodies is another convincing argument 
that the antibody-mediated response is 
critical (10). Thus, because rituximab 
is associated with long-lasting B-cell 
depletion and, in some patients, a de-
crease in immunoglobulin, it may lead 
to an increased risk for EV encephali-
tis. Although EV encephalitis seems to 
be rare in patients who receive ritux-
imab treatment, cases may have been 
underdiagnosed. To detect this condi-
tion and prevent possible deaths, phy-
sicians should routinely screen for EV 
RNA in patients receiving anti-CD20 
therapy who have neurologic symp-
toms and should consider the early ad-
ministration of immunoglobulin.
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To the Editor: Noroviruses 
(NoVs) are the most common cause of 
foodborne and waterborne outbreaks 
of gastroenteritis in persons from all 
age groups in industrialized and de-
veloping countries (1). Although NoV 
outbreaks occur throughout the year, 
activity increases in the winter months, 
especially in the countries with a tem-
perate climate. As expected, during 
the last few months of 2012, outbreaks 
of NoV gastroenteritis markedly in-
creased in Europe and the United 
States (2–4). These increases corre-
sponded with the emergence of a vari-
ant of genotype GII.4, Sydney/2012, 
which was first reported from Austra-
lia in March 2012 and, subsequently, 
in the United States, Belgium, Den-
mark, Scotland, and Japan (2,5–7).
We identified the NoV GII.4 vari-
ant Sydney/2012 through hospital 
surveillance on diarrhea etiology in 
Bangladesh in December 2011 and 
then throughout 2012. These strains 
came from 3 hospitals in Dhaka, Mat-
lab, and Mirzapur, where ≈150,000 
patients with diarrhea are treated an-
nually. We randomly selected 795 fe-
cal specimens from patients of all ages 
who sought treatment for diarrhea in 
these hospitals during 2010–2012 and 
detected NoV RNA in 90 (33.6%), 72 
(27.9%), and 92 (34.2%) samples in 
2010, 2011, and 2012, respectively, 
by performing real-time PCR (8). For 
characterization, we amplified and se-
quenced 108 samples on the basis of 
the capsid genes (9).
Ages of diarrhea patients with 
NoV infection ranged from 1 month 
to 91 years (median 15 months; mean 
11.9 years). Most (66%) NoV-positive 
patients were <5 years of age. Infection 
rates were lowest in patients <3 months 
(2.1%) and 5–18 years (2.5%) of age. 
A high number of NoV infections were 
recorded in adults (28.8% in patients 
>18 years of age). NoVs were detected 
throughout the year, and no clear sea-
sonal peaks were observed.
Overall, GII was the most pre-
dominant genogroup (66.1%), fol-
lowed by GI (18.1%) and GIV (3.9%). 
Mixed infections were detected in 
11.8% of samples. We observed a high 
diversity in the GII genogroup and 
identified at least 11 different geno-
types within the group, in which GII.4 
constituted 30.1% of all GII strains. 
Until December 2011, the GII.4 vari-
ant NewOrleans/2009 was the most 
predominant strain (Figure). However, 
the new GII.4 variant, Sydney/2012, 
replaced the old variant and appeared 
as the dominant strain in 2012. We 
constructed a phylogenetic tree on the 
basis of 1,026 bases around the junc-
tion region of pol and cap genes, and it 
revealed that the newly identified vari-
ant has evolved from previous NoV 
GII.4 variants Apeldoorn/2007 and 
NewOrleans/2009 (data not shown).
NoVs, old and new, remain a sub-
stantial threat to human health, with a 
new variant emerging every 2–3 years. 
The Sydney/2012 strain appears to 
have replaced the previously predomi-
nant strain, but its clinical effects and 
epidemiology are largely unknown 
and warrant further investigation.
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Figure.	 Distribution	 of	 108	 norovirus	 (NoV)	 genotypes	 in	 Bangladesh,	 2010–2012.	 Bar	
chart	shows	the	percentage	of	NoV	genotypes.	Mixed	genotypes	comprise	NoV	GI	and	
GII.	GI	comprises	GI.1,	GI.3,	GI.4,	GI.5,	and	GI.9.	GII.others	comprises	GII.2,	GII.3,	GII.4,	
GII.6,	GII.10,	GII.13,	GII.16,	GII.17,	and	GII.21.
